Project Grant R01AI182977
Award Date
11/22/24
Completion Date
10/31/29
Dollars Obligated
$857K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Nutley, NJ 07110, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $265,650 to study the evolutionary dynamics of the fungal pathogen Candida glabrata in the gastrointestinal tract of mice. The research aims to elucidate how antifungal drug treatment and immune dysfunction impact the adaptation and evolution of gut-colonizing C. glabrata, with the goal of informing improved strategies...
This $893,203 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the mechanisms of IL-17-mediated kidney tissue protection in disseminated candidiasis, a severe bloodstream infection caused by the fungus Candida albicans. The research aims to define the role of the NDUFS4 gene in protecting renal tubular epithelial cells from mitochondrial...
This $170,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Prokaryotics Incorporated to develop novel antifungal therapeutics. The key objectives are to conduct structural biology studies on the fungal enzyme MCD4, which is involved in glycosylphosphatidylinositol (GPI) biosynthesis, and to leverage these insights to synthesize and evaluate new antifungal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $251,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas M.D. Anderson Cancer Center. The grant is focused on developing novel chimeric antigen receptor (CAR) T-cell and CAR-macrophage based cell therapies to target and recruit the host immune system to protect against systemic Candida infections, which are a major threat to immunocompromised patients. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Brown University a 5-year, $866,825 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the fundamental mechanisms by which the fungus Candida albicans colonizes the gastrointestinal (GI) tract. The research aims to determine how C. albicans morphology and the toxin candidalysin influence the fungus's ability to thrive in the GI tract, particularly in the presence of high...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,990 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to examine the role of the Candida albicans TOR1 kinase and its N-terminal heat repeats in enabling this fungal pathogen to withstand oxidative stress imposed by the host immune system. The goal is to define the interactions between TOR1 and its N-terminal...
This $233,670 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the genetic mechanisms underlying skin colonization by the emerging fungal pathogen Candida auris. The research, conducted by the Regents of the University of Michigan, aims to elucidate the clade-specific genetic circuitry that enables C. auris to achieve high levels of...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to understand the molecular and mechanistic bases of biofilm microbial communities. The project aims to investigate how transcriptional networks regulate gene expression during biofilm development, with a focus on single-species biofilms formed by the fungal pathogen Candida albicans as well as dual-species biofilms with...
This Project Grant award of $558,747, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate a novel link between the fungal virulence factor calcineurin, amino acid permease, and protein kinase A in the pathogen Mucor that causes the life-threatening infection mucormycosis. The research aims to identify key transcription factors regulated by calcineurin, elucidate the...
This $416,396 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance the development of natural phenolic compounds, specifically caffeic acid phenethyl ester (CAPE) and ellagic acid (EA), for the management of oral candidiasis. The award supports the following key activities: Optimization of hydrogels loaded with EA and/or CAPE to achieve maximal compound release and...